[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BRPI1011031B8 - composição líquida farmaceuticamente aceitável e kit - Google Patents

composição líquida farmaceuticamente aceitável e kit

Info

Publication number
BRPI1011031B8
BRPI1011031B8 BRPI1011031A BRPI1011031A BRPI1011031B8 BR PI1011031 B8 BRPI1011031 B8 BR PI1011031B8 BR PI1011031 A BRPI1011031 A BR PI1011031A BR PI1011031 A BRPI1011031 A BR PI1011031A BR PI1011031 B8 BRPI1011031 B8 BR PI1011031B8
Authority
BR
Brazil
Prior art keywords
kit
pharmaceutically acceptable
acceptable liquid
levodopa
disease
Prior art date
Application number
BRPI1011031A
Other languages
English (en)
Inventor
Nemas Mara
Yacoby-Zeevi Oron
Original Assignee
Neuroderm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42320738&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI1011031(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neuroderm Ltd filed Critical Neuroderm Ltd
Publication of BRPI1011031A2 publication Critical patent/BRPI1011031A2/pt
Publication of BRPI1011031B1 publication Critical patent/BRPI1011031B1/pt
Publication of BRPI1011031B8 publication Critical patent/BRPI1011031B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C243/00—Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
    • C07C243/10—Hydrazines
    • C07C243/12—Hydrazines having nitrogen atoms of hydrazine groups bound to acyclic carbon atoms
    • C07C243/16—Hydrazines having nitrogen atoms of hydrazine groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
    • C07C243/18—Hydrazines having nitrogen atoms of hydrazine groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

sal de arginina de um agente ativo, composição líquida ou em gel farmaceuticamente aceitável, kit, método para tratamento de uma desordem neurológica e método para tratar ou amenizar a doença de parkinson em um paciente que necessite deste. divulgados neste documento estão sais de arginina de carbidopa e levodopa e composições que incluem, por exemplo, sal de arginina de carbidopa adequado para administração continua para o tratamento de doenças neurológicas ou motoras ou doenças como a sindrome das pernas inquietas, doença de parkinson, parkinsonismo secundário, psp, msa, als, síndrome shy-drager e condições resultantes e lesão cerebral, incluindo monóxido de carbono ou intoxicação por manganês, juntamente com as administração de levodopa.
BRPI1011031A 2009-05-19 2010-05-17 composição líquida farmaceuticamente aceitável e kit BRPI1011031B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17951109P 2009-05-19 2009-05-19
US61/179,511 2009-05-19
PCT/IL2010/000400 WO2010134074A1 (en) 2009-05-19 2010-05-17 Compositions for continuous administration of dopa decarboxylase inhibitors

Publications (3)

Publication Number Publication Date
BRPI1011031A2 BRPI1011031A2 (pt) 2016-08-16
BRPI1011031B1 BRPI1011031B1 (pt) 2020-06-23
BRPI1011031B8 true BRPI1011031B8 (pt) 2021-05-25

Family

ID=42320738

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1011031A BRPI1011031B8 (pt) 2009-05-19 2010-05-17 composição líquida farmaceuticamente aceitável e kit

Country Status (26)

Country Link
US (9) US8193243B2 (pt)
EP (3) EP3777839A1 (pt)
JP (3) JP5643297B2 (pt)
KR (2) KR101641401B1 (pt)
CN (2) CN102438587B (pt)
AR (3) AR078413A1 (pt)
AU (1) AU2010250766B2 (pt)
BR (1) BRPI1011031B8 (pt)
CA (1) CA2761624C (pt)
CL (1) CL2011002895A1 (pt)
CY (1) CY1119495T1 (pt)
DK (2) DK2432454T3 (pt)
ES (2) ES2840748T3 (pt)
HR (2) HRP20170805T1 (pt)
HU (2) HUE033388T2 (pt)
IL (1) IL216383A (pt)
LT (1) LT2432454T (pt)
MX (2) MX364974B (pt)
NZ (1) NZ596963A (pt)
PL (2) PL3192500T3 (pt)
PT (2) PT3192500T (pt)
RU (3) RU2678839C2 (pt)
SG (3) SG10201505101VA (pt)
SI (1) SI2432454T1 (pt)
WO (1) WO2010134074A1 (pt)
ZA (1) ZA201109037B (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN192600B (pt) * 1996-10-18 2004-05-08 Hoechst Celanese Corp
KR101641401B1 (ko) * 2009-05-19 2016-07-20 뉴로덤 엘티디 Ｄｏｐａ 데카르복실라제 억제제의 연속투여용 조성물
WO2012066538A1 (en) * 2010-11-15 2012-05-24 Neuroderm Ltd Continuous administration of l-dopa, dopa decarboxylase inhibitors, catechol-o-methyl transferase inhibitors and compositions for same
CN107693486A (zh) 2012-06-05 2018-02-16 纽罗德姆有限公司 包含阿朴吗啡和有机酸的组合物及其用途
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
CN103845318A (zh) * 2012-12-07 2014-06-11 天津市汉康医药生物技术有限公司 恩他卡朋分散片
HRP20211442T1 (hr) * 2013-03-13 2022-02-04 Neuroderm Ltd Kombinacija za liječenje parkinsonove bolesti
WO2015069773A1 (en) * 2013-11-05 2015-05-14 Synagile Corporation Devices and methods for continuous drug delivery via the mouth
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
DK3777833T3 (da) * 2014-03-13 2023-12-18 Neuroderm Ltd Dopa-decarboxylase-inhibitorsammensætninger
PL3188725T3 (pl) * 2014-09-04 2021-08-02 Lobsor Pharmaceuticals Aktiebolag Kompozycje farmaceutyczne zawierające lewodopę, inhibitor dekarboksylazy dopaminy i inhibitor comt oraz sposób ich podawania
AU2015335941B2 (en) 2014-10-21 2021-04-01 Abbvie Inc. Carbidopa and L-dopa prodrugs and their use to treat Parkinson's disease
MA41377A (fr) 2015-01-20 2017-11-28 Abbvie Inc Gel intestinal de lévodopa et de carbidona et procédés d'utilisation
JP6982870B2 (ja) 2015-05-06 2021-12-17 シンアジャル コーポレイション 薬物粒子を含有する医薬懸濁液、それらの投与のためのデバイス、およびそれらの使用方法
US10555922B2 (en) 2015-09-04 2020-02-11 Lobsor Pharmaceuticals Aktiebolag Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor
CA3006028A1 (en) 2015-11-24 2017-06-01 Neuroderm, Ltd. Pharmaceutical compositions comprising levodopa amide and uses thereof
EP3442516A4 (en) * 2016-04-11 2019-12-18 University of Canberra OPHTHALMIC COMPOSITIONS WITH LEVODOPA, AN ANTIOXIDANE AND AN AQUEOUS SUBSTANCE
US10064834B2 (en) 2016-05-09 2018-09-04 Texas Tech University System Carbidopa for the treatment of cancer
DK3634384T3 (da) 2017-06-05 2021-04-19 Dizlin Pharmaceuticals Ab Levodopa-infusionsopløsning
US20230123806A1 (en) * 2017-07-07 2023-04-20 Neuroderm, Ltd. Device for subcutaneous delivery of fluid medicament
EP3773532A4 (en) * 2018-03-29 2022-11-02 Avion Pharmaceuticals, LLC FRACTIONAL LEVODOPA DOSAGE AND USE
US20220226269A1 (en) * 2019-06-12 2022-07-21 President And Fellows Of Harvard College Methods and compositions for modulation of an interspecies gut bacterial pathway for levodopa metabolism
EP4203939A4 (en) * 2020-08-31 2024-11-06 Purdue Pharma Lp COMPOSITIONS AND METHODS FOR LEVODOPA RELEASE
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
AU2022428092A1 (en) * 2022-01-03 2024-07-25 Neuroderm, Ltd. Methods and compositions for treating parkinson's disease

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3769424A (en) * 1970-10-01 1973-10-30 Merck & Co Inc Composition and method of treating dopamine deficiency in brain tissue
AU6889274A (en) * 1973-05-17 1975-11-20 Astra Laekemedel Ab Treatment of neurological disorders
US3936495A (en) * 1973-11-27 1976-02-03 Merck & Co., Inc. Purification process
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4241082A (en) 1977-09-02 1980-12-23 Sankyo Company Limited Agents for promoting reproductive ability of domestic animals
JPS5450700A (en) 1977-09-28 1979-04-20 Sankyo Co Glazing agent of animal leather
JPS6021570B2 (ja) * 1978-07-04 1985-05-28 三共株式会社 ド−パ類の高濃度製剤の製法
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4642316A (en) * 1985-05-20 1987-02-10 Warner-Lambert Company Parenteral phenytoin preparations
ATE76747T1 (de) * 1986-06-10 1992-06-15 Chiesi Farma Spa Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen.
US4684666A (en) * 1986-08-19 1987-08-04 Haas Pharmaceuticals, Inc. Stabilized liquid analgesic compositions
US4963568A (en) 1989-05-31 1990-10-16 Abbott Laboratories Dopamine agonists
WO1992007561A1 (fr) * 1990-10-30 1992-05-14 Ss Pharmaceutical Co., Ltd. Preparation d'un gel anti-inflammatoire et analgesique
US5877176A (en) * 1991-12-26 1999-03-02 Cornell Research Foundation, Inc. Blocking induction of tetrahydrobiopterin to block induction of nitric oxide synthesis
CA2143070C (en) * 1994-02-22 2001-12-18 Pankaj Modi Oral controlled release liquid suspension pharmaceutical formulation
GB9523833D0 (en) 1995-11-22 1996-01-24 Boots Co Plc Medical treatment
US5861423A (en) * 1997-02-21 1999-01-19 Caldwell; William Scott Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds
WO1999048876A1 (en) * 1998-03-20 1999-09-30 Warner-Lambert Company Crystalline sodium phenytoin monohydrate
US7201923B1 (en) * 1998-03-23 2007-04-10 General Mills, Inc. Encapsulation of sensitive liquid components into a matrix to obtain discrete shelf-stable particles
DK1077692T3 (da) 1998-05-15 2004-12-06 Warner Lambert Co Aminosyrestabiliserede gabapentin- og pregabalinpræparater og fremgangsmåder til fremstilling deraf
US6274168B1 (en) * 1999-02-23 2001-08-14 Mylan Pharmaceuticals Inc. Phenytoin sodium pharmaceutical compositions
US6716452B1 (en) * 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
WO2000054773A1 (en) 1999-03-12 2000-09-21 Nitromed, Inc. Dopamine agonists in combination with nitric oxide donors, compositions and methods of use
FI109453B (fi) * 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus
US7479498B2 (en) * 1999-08-23 2009-01-20 Phoenix Biosciences, Inc. Treatments for viral infections
US6348965B1 (en) * 1999-09-24 2002-02-19 Henry Palladino Solid state fluorescence and absorption spectroscopy
SE0001151D0 (sv) 2000-03-31 2000-03-31 Amarin Dev Ab Method for producing a controlled-release composition
US20020028799A1 (en) 2000-07-06 2002-03-07 Naylor Alasdair Mark Treatment of male sexual dysfunction
GB0017387D0 (en) * 2000-07-14 2000-08-30 Pfizer Ltd Novel enzyme
US20020099013A1 (en) 2000-11-14 2002-07-25 Thomas Piccariello Active agent delivery systems and methods for protecting and administering active agents
US20030119714A1 (en) 2000-12-15 2003-06-26 Naylor Alasdair Mark Treatment of male sexual dysfunction
US20050233945A1 (en) * 2003-07-18 2005-10-20 Larry Brown Methods for fabrication, uses and compositions of small spherical particles of insulin prepared by controlled phase separation
EP1450901A4 (en) 2001-12-10 2005-05-25 Bristol Myers Squibb Co (1-PHENYL-2-HETEROARYL) ETHYL-GUANIDINE COMPOUNDS AS AN INHIBITORS OF MITOCHONDRIAL F1F0 ATP HYDROLASE
EP1496868A1 (en) * 2002-04-11 2005-01-19 Ranbaxy Laboratories, Ltd. Controlled release pharmaceutical compositions of carbidopa and levodopa
US7985422B2 (en) 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
JP4602903B2 (ja) 2002-10-10 2010-12-22 モルフォケム アクチェンゲゼルシャフト フュア コンビナトリシェ ヘミー 抗菌活性を有する新規化合物
US7589233B2 (en) * 2003-07-29 2009-09-15 Signature R&D Holdings, Llc L-Threonine derivatives of high therapeutic index
US8173840B2 (en) 2003-07-29 2012-05-08 Signature R&D Holdings, Llc Compounds with high therapeutic index
GB0319935D0 (en) 2003-08-26 2003-09-24 Cipla Ltd Polymorphs
JP5160786B2 (ja) * 2003-08-29 2013-03-13 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 医薬組成物及びレボドパ及びカルビドパの使用方法
US20050053669A1 (en) 2003-09-05 2005-03-10 Boehringer Ingelheim International Gmbh Administration form for the oral application of poorly soluble acidic and amphorteric drugs
CN1968680A (zh) * 2003-10-31 2007-05-23 阿尔扎公司 促进加巴喷丁和普加巴林的吸收的组合物和剂型
WO2005041923A1 (en) * 2003-10-31 2005-05-12 Alza Corporation Compositions and dosage forms for enhanced absorption of metformin
WO2005099678A1 (en) 2004-04-06 2005-10-27 Transform Pharmaceuticals, Inc. Pharmaceutical compositions and method of using levodopa and carbidopa
SE0401842D0 (sv) * 2004-07-12 2004-07-12 Dizlin Medical Design Ab Infusion and injection solution of levodopa
EP1797109B1 (en) * 2004-09-09 2016-02-24 Yeda Research And Development Co., Ltd. Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof
WO2006037061A2 (en) * 2004-09-28 2006-04-06 Farouk Karoum Compositions and methods of using d-dopa to treat parkinson's disease
WO2006043532A1 (ja) * 2004-10-19 2006-04-27 Ono Pharmaceutical Co., Ltd. パーキンソン病治療剤
DE102006021872B4 (de) 2006-05-11 2008-04-17 Sanofi-Aventis 4,5-Diphenyl-pyrimidinyl-oxy oder -mercapto substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CA2653683A1 (en) 2006-05-31 2007-12-06 Solvay Pharmaceuticals Gmbh Long term 24-hour intestinal administration of levodopa/carbidopa
CA2606658A1 (en) 2006-10-13 2008-04-13 Mike Tyers Compositions and methods for treating neurological disorders or damage
JP5631734B2 (ja) * 2007-04-06 2014-11-26 トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド 流体薬物を供給するためのシステム及び方法
CN101669925B (zh) 2008-09-10 2011-08-10 天津药物研究院 干粉吸入剂、其制备方法和用途
US20130253056A1 (en) 2009-05-19 2013-09-26 Neuroderm, Ltd. Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same
KR101641401B1 (ko) 2009-05-19 2016-07-20 뉴로덤 엘티디 Ｄｏｐａ 데카르복실라제 억제제의 연속투여용 조성물
CN101987081B (zh) 2010-07-16 2012-08-08 钟术光 一种控释制剂
KR101187064B1 (ko) 2010-07-18 2012-09-28 주식회사 바이오폴리메드 양이온성 지질, 이의 제조 방법 및 이를 포함하는 세포내 이행성을 갖는 전달체
US10150792B2 (en) 2010-11-08 2018-12-11 Synthonics, Inc. Bismuth-containing compounds, coordination polymers, methods for modulating pharmacokinetic properties of biologically active agents, and methods for treating patients
WO2012066538A1 (en) 2010-11-15 2012-05-24 Neuroderm Ltd Continuous administration of l-dopa, dopa decarboxylase inhibitors, catechol-o-methyl transferase inhibitors and compositions for same
US9415108B2 (en) 2010-11-15 2016-08-16 Neuroderm, Ltd. Compositions for transdermal delivery of active agents
JP2014508113A (ja) 2010-12-10 2014-04-03 シンアジャイル コーポレーション 皮下注入可能なレボドパプロドラッグ組成物及び注入方法
US20130116215A1 (en) 2011-10-28 2013-05-09 Mireia Coma Combination therapies for treating neurological disorders
HRP20211442T1 (hr) 2013-03-13 2022-02-04 Neuroderm Ltd Kombinacija za liječenje parkinsonove bolesti
DK3777833T3 (da) 2014-03-13 2023-12-18 Neuroderm Ltd Dopa-decarboxylase-inhibitorsammensætninger

Also Published As

Publication number Publication date
EP2432454B1 (en) 2017-03-01
EP3777839A1 (en) 2021-02-17
MX364974B (es) 2019-05-16
LT2432454T (lt) 2017-07-10
RU2015115064A (ru) 2015-11-20
EP2432454A1 (en) 2012-03-28
AU2010250766A1 (en) 2012-01-12
PL3192500T3 (pl) 2021-04-06
ZA201109037B (en) 2013-02-27
BRPI1011031A2 (pt) 2016-08-16
SG176159A1 (en) 2011-12-29
WO2010134074A1 (en) 2010-11-25
US9993451B2 (en) 2018-06-12
US9040589B2 (en) 2015-05-26
US20110269833A1 (en) 2011-11-03
US9101663B2 (en) 2015-08-11
ES2840748T3 (es) 2021-07-07
JP5921002B2 (ja) 2016-05-24
US20100298428A1 (en) 2010-11-25
PT3192500T (pt) 2021-01-05
KR20160091424A (ko) 2016-08-02
RU2559083C9 (ru) 2016-01-20
US20140249231A1 (en) 2014-09-04
HUE033388T2 (en) 2017-12-28
AR078413A1 (es) 2011-11-09
EP3192500A1 (en) 2017-07-19
HRP20170805T1 (hr) 2017-08-25
RU2011149976A (ru) 2013-06-27
NZ596963A (en) 2014-01-31
AR117502A2 (es) 2021-08-11
BRPI1011031B1 (pt) 2020-06-23
MX2011012315A (es) 2011-12-16
PL2432454T3 (pl) 2017-10-31
JP6157678B2 (ja) 2017-07-05
SI2432454T1 (sl) 2017-09-29
CN104546700B (zh) 2017-06-06
HUE052685T2 (hu) 2021-05-28
JP2015017144A (ja) 2015-01-29
US20190125708A1 (en) 2019-05-02
JP2012527447A (ja) 2012-11-08
JP2016121199A (ja) 2016-07-07
KR101709904B1 (ko) 2017-02-23
RU2559083C2 (ru) 2015-08-10
CL2011002895A1 (es) 2012-10-12
CN102438587B (zh) 2015-08-19
US7863336B2 (en) 2011-01-04
IL216383A0 (en) 2012-01-31
HRP20202038T1 (hr) 2021-03-05
US20230321019A1 (en) 2023-10-12
SG10201709016RA (en) 2017-11-29
US8193243B2 (en) 2012-06-05
AR117412A2 (es) 2021-08-04
US20140249230A1 (en) 2014-09-04
CN104546700A (zh) 2015-04-29
SG10201505101VA (en) 2015-07-30
ES2627655T3 (es) 2017-07-31
KR20120027371A (ko) 2012-03-21
CA2761624C (en) 2016-10-18
US20160151317A1 (en) 2016-06-02
US9040590B2 (en) 2015-05-26
US20210077442A1 (en) 2021-03-18
DK2432454T3 (en) 2017-06-19
PT2432454T (pt) 2017-06-12
CN102438587A (zh) 2012-05-02
JP5643297B2 (ja) 2014-12-17
US20100298429A1 (en) 2010-11-25
IL216383A (en) 2016-02-29
KR101641401B1 (ko) 2016-07-20
RU2678839C2 (ru) 2019-02-04
RU2019101159A (ru) 2020-07-16
AU2010250766B2 (en) 2015-04-09
CA2761624A1 (en) 2010-11-25
CY1119495T1 (el) 2018-03-07
DK3192500T3 (da) 2020-12-21
EP3192500B1 (en) 2020-12-02

Similar Documents

Publication Publication Date Title
BRPI1011031B8 (pt) composição líquida farmaceuticamente aceitável e kit
BR112015027282A8 (pt) formulação líquida e kit compreendendo fenfluramina, e usos da mesma no tratamento de síndrome de dravet
EP3818991A3 (en) Compositions and methods for treating diseases
BR112014010275A2 (pt) formulações para tratamento de diabetes
MX2013007189A (es) Metodos y composiciones adecuados para manejar glucosa en sangre en animales.
BR112013026032A2 (pt) composições nutricionais incluindo ácidos graxos de cadeia ramificada para cicatrização de ferida
CY1116344T1 (el) Κυτταρα προερχομενα απο ιστο ομφαλιου λωρου για την θεραπεια νευροπαθητικου πονου και σπαστικοτητας
WO2013169864A3 (en) TETRAHYDRO[1,8]NAPHTHYRIDINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORƴ AND THE TREATMENT OF DISEASE
EA201391154A2 (ru) Способы и композиции для нацеливания на адипоциты у млекопитающих
BR112015015108A2 (pt) cateter com marcações para facilitar o alinhamento
BR112013005673A2 (pt) uso de lipase de ácido lisossomal para tratamento de deficiência de lipase de ácido lisossomal em pacientes
CY1115725T1 (el) Ενωσεις, συνθεσεις και μεθοδοι για την θεραπευτικη αγωγη των βητα-αμυλοειδικων ασθενειων και συνουκλεϊνοπαθειων
MX2015001716A (es) Niclosamida para el tratamiento de tumores solidos.
BR112014003071A2 (pt) tratamento de doença vascular periférica com o uso de células derivadas do tecido do cordão umbilical
BR112014001170A2 (pt) cateter, especialmente um cateter permanente, para tratamento de problemas funcionais e/ou doenças da bexiga e/ou próstata
BR112015019802A2 (pt) formulações farmacêuticas de nitrito e usos das mesmas
AU2018253538A1 (en) Levodopa formulations for rapid relief of parkinson&#39;s disease
CO6592030A2 (es) Uso de la tasa de dilatación ventricular en el tratamiento de la enfermedad de alzheimer con inmunoglobulina intravenosa
IN2014CN03333A (pt)
BR112013025197A2 (pt) métodos para tratar doença de alzheimer e para avaliar a eficáca de uma terapia destinada a tratar doença de alzheimer
CR20110687A (es) Procedimientos de uso del factor liberador de corticotropina para el tratamiento de cancer
BRPI1009892A2 (pt) método ex-vivo para avaliar a eficácia de um tratamento em um paciente, e, kit para testar se um paciente está respondendo terapeuticamente a um método de tratamento compreendendo administração de uma composição imunogênica
MX2022014577A (es) Gel intestinal de levodopa y carbidopa y metodos de uso.
UA112981C2 (uk) Варіант людського gdnf
EA201200753A1 (ru) Фармацевтическая композиция для лечения заболеваний мочевого пузыря

Legal Events

Date Code Title Description
B15I Others concerning applications: loss of priority

Free format text: PERDA DA PRIORIDADE US 61/179,511 DE 19/05/2009 , CONFORME AS DISPOSICOES PREVISTAS NA LEI 9.279 DE 14/05/1996 (LPI) ART. 16 7O, ITEM 28 DO ATO NORMATIVO 128/97 E NO ART. 29 DA RESOLUCAO INPI-PR 77/2013. ESTA PERDA SE DEU PELO FATO DE O DEPOSITANTE CONSTANTE DA PETICAO DE REQUERIMENTO DE ENTRADA NA FASE NACIONAL SER DISTINTO DAQUELE QUE DEPOSITOU O PEDIDO ANTERIOR CUJA PRIORIDADE E REIVINDICADA E APRESENTOU COPIA DO CORRESPONDENTE DOCUMENTO DE CESSAO EM 28/02/202012, CONTUDO O PRAZO PARA A APRESENTACAO DA CESSAO DO DIREITO DE PRIORIDADE EXPIRAVA EM 18/01/2012 (60 DIAS APOS A ENTRADA DA FASE NACIONAL DO BRASIL), CONFORME AS DISPOSICOES PREVISTAS NA LEI 9.279 DE 14/05/1996 (LPI) ART. 16 6O

B12F Other appeals [chapter 12.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 23/06/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/05/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF